Share Name Share Symbol Market Type Share ISIN Share Description
E-therapeutics Plc LSE:ETX London Ordinary Share GB00B2823H99 ORD 0.1P
  Price Change % Change Share Price Shares Traded Last Trade
  -0.05 -2.0% 2.45 1,320,074 13:13:27
Bid Price Offer Price High Price Low Price Open Price
2.40 2.50 2.50 2.40 2.50
Industry Sector Turnover (m) Profit (m) EPS - Basic PE Ratio Market Cap (m)
Pharmaceuticals & Biotechnology 0.04 -5.09 -1.49 7
Last Trade Time Trade Type Trade Size Trade Price Currency
16:17:41 O 403 2.478 GBX

E-therapeutics (ETX) Latest News

More E-therapeutics News
E-therapeutics Takeover Rumours

E-therapeutics (ETX) Share Charts

1 Year E-therapeutics Chart

1 Year E-therapeutics Chart

1 Month E-therapeutics Chart

1 Month E-therapeutics Chart

Intraday E-therapeutics Chart

Intraday E-therapeutics Chart

E-therapeutics (ETX) Discussions and Chat

E-therapeutics Forums and Chat

Date Time Title Posts
17/10/201912:45ETX-Fighting MRSA & winning.1,047
27/6/201912:55ETX, The Boss & the Company2
18/5/201310:49ETX : Stocktube Vid74

Add a New Thread

E-therapeutics (ETX) Most Recent Trades

Trade Time Trade Price Trade Size Trade Value Trade Type
2019-10-17 15:17:422.484039.99O
2019-10-17 13:48:262.48100,3832,487.49O
2019-10-17 13:17:492.40241,2335,792.00O
2019-10-17 12:36:242.50320,0008,000.00O
2019-10-17 12:13:112.4850,0001,239.00O
View all E-therapeutics trades in real-time

E-therapeutics (ETX) Top Chat Posts

E-therapeutics Daily Update: E-therapeutics Plc is listed in the Pharmaceuticals & Biotechnology sector of the London Stock Exchange with ticker ETX. The last closing price for E-therapeutics was 2.50p.
E-therapeutics Plc has a 4 week average price of 2.40p and a 12 week average price of 2.20p.
The 1 year high share price is 7.50p while the 1 year low share price is currently 1.43p.
There are currently 268,389,125 shares in issue and the average daily traded volume is 159,382 shares. The market capitalisation of E-therapeutics Plc is £6,575,533.56.
paulcon1: The share price dropped 5p in 6 months with no news so there is no reason to believe the share price would have risen 5p in 6 days on no news 😵 I am a little surprised the share price is not around 4p atm but am looking it to be around 6.5 - 7.00p (natural base level) in 4-5 weeks from now (on no news) and even more on the back of a strong contract win or stellar partnership or positive drug progress report. Let's see.. GL and IMHO and DYOR
pwhite73: The share price is standing at 3p and not £1.00 because retail investors have lost interest since Woodford sold out. I could ask you if the company's broker has put a valuation of 21p on the share price why is it currently sitting at 3p. This all comes back to what I said earlier it is only news that drives the share price not fundamentals. If any retail investors were genuinely interested in fundamentals they would not be investing in the AIM. 80% of investors lose money on the AIM. This figure rises to about 95% if they decide to hold long term. Don't make excuses for ETX. Whether you decide to hold for 24 hrs, 24 days, 24 weeks, 24 months or 24 years this share price will not re-rate and find its true value without positive news.
paulcon1: For short term, day trading, news flow (positive or negative) is the driving force for share price movement.. Fundamentals (P&L), cash balance, IP's, Assets etc are essential for long term investors, broker forecasts, Institutional Investors, mergers and acquisitions and operational decisions. I am confused as to your stance as you are stating there has been a complete lack of news yet the share price has risen and why does it stand at 3p if fundamentals do not play a part. Why not 1p or £1.00 IMHO
pwhite73: ETX is an AIM/microcap stock. These stocks are 100% news driven not fundamentals driven. Cash balances, IPs and assets do not determine the share price. This is why when they issue bad news everything goes out the window and they can drop up to 75% in a single day. Conversely they can also multi-bag on good news in a single day. Without news ETX will continue to drop. The Woodford selling that started in early June should have sent the share price lower but it had the opposite effect. This is because it provided news on ETX and people began to look at the company once again, and many associated the fall prior to June with Woodford selling when it was not him. Now that Woodford is and no longer an ETX related news item the stock has continued on its downward slide. A few people have looked at the fundamentals again and decided it is worth a punt. This seems to have put a floor under the share price of 2.50p - 3.00p. But this is only temporary. As the subsequent months go by without further operational news the slide will restart again. ETX and ETX alone are to blame for the decimation of its share price.
paulcon1: Take Mr Woodford out of it for a second, why would the ETX share price drop from 6.5p - 1.5p over the space of 6 months, when the fundamentals remain the same. - 6.5p was excessive and pumped up? - Lack of news? - £8m is the correct mkt value Or maybe the impact of a large seller/sellers on low volume over an extended period of time. For me, I'm looking forwards the share price is around 3p (£8m mkt value) and that seems remarkably low given cash balance, IP's and potential IMHO
74tom: Pwhite, the share price when the first notification can through shows the impact of him selling 10m shares in such a low volume stock, see below for more detail which I posted on LSE on 26th June; “I think Woodford first lodged his sell order on ETX before the start of 2019 - on 1st January the share price was 6.35 Volume during January was a grand total of 197k shares, yet the price ended the month at 5.25 In Feb there were 555k shares traded with the price falling to 4.8 There was a 5m sell on 20th March that coincided with a 15m volume day and a fall down to 2.8 - so the first 5m of Woodford clearing. From there until the end of April there was just 3m volume and the price stayed at 3p ish May saw another 3m volume with the price falling to 2p, finally seeing the the first Woodford notification on 3rd June confirming that he’d sold 10m shares and explaining the fall. Since then the price has fallen further before finally attracting widespread attention at 1.6p, now we have had 69m shares traded in 4 days - more than in the previous 249 trading days combined (and that includes 30m trades on 5/12 when the Novo agreement was announced, and the share price remained stuck at 6.63p). With such a historically low volume of trades (you can download the daily data from the investors page of the ETX site), it’s no wonder that a 10m sell from Woodford decimated the price! The recent volume has meant that PI’s have actually dug into ETX and discovered a company in better shape than most AIM pharmas.”
paulcon1: Dub Fwiw, I agree with your comment, it appears(for now) the last week or so has been the MM's manipulating the share price up and down on the back of the Woodford exit. The MKT value of ETX does seem very cheap though and the pre 'fire sale of shares'SP of 6.5-7.00p does seems a natural base level. ETX do look a very professional company with, potentially, a number of effective and relevant products based around game-changing technology. Good luck with your investment IMHO
mam fach: Can anyone explain why Woodford selling makes difference to share price ? Or is the theory that him being a holder was holding share price back?
tidy 2: Surfi, beginning on December 26 2018 – when the share price was 6.75p – E-therapeutics has suffered a rare capitulation that is wholly disconnected to its fundamentals. Selling cascaded to extremes as stop losses were sequentially triggered, battering this junior pharma to exceedingly low levels.While very challenging psychologically, capitulations are super-bullish. They rapidly exhaust all near-term selling potential, leaving stocks wildly oversold and undervalued which, in turn, ushers in major new uplegs.The word capitulation, after all, means 'the act of surrendering or giving up'. That's exactly what's happened in this extraordinary selling event; investors simply bolted for the exits.Exceptionally-bearish investor sentiment hit the company following a gargantuan fire-sale campaign by Woodford Investment Management which proved to be pretty nasty. And since then, on June 26 2019, WIM had 17,992,900 shares left, around 6.67% of the company's share capital.Well, at 11:05am this morning, a staggering 35m shares had changed hands implying the full absorption of WIM's balance. To this end, I'm expecting two things to happen in the next 5hrs: first, a TR-1 notification confirming WIM's exit, and second, the commencement of a full re-rate of the shares back to their pre-fire sale trading point of 6.75p.But aside from that, and having been invested in the company since August 2018, I can categorically confirm that e-Therapeutics is currently profoundly mispriced. On this point, pay strong attention to the company's cash balance, its spectacular stable of ground-breaking therapies and collaborations, the imminent milestone payments, and its house broker's share price guidance.
1kg hamburger: Surely he will want this to be above 3.0p min if he wants to exercise. Oxford, UK, 29(th) of March 2019: e-therapeutics plc (AIM: ETX), the network-driven drug discovery company, announces that on 28(th) March2019, it granted 2,000,000 options over its ordinary shares of 0.1 pence each under the e-Therapeutics Performance Share Plan 2013 (One-Off Awards 2016) to Raymond Barlow, Chief Executive Officer of the Company at an exercise price of 2.7 pence per share, being equivalent to the closing share price on the day before grant.
E-therapeutics share price data is direct from the London Stock Exchange
Your Recent History
Register now to watch these stocks streaming on the ADVFN Monitor.

Monitor lets you view up to 110 of your favourite stocks at once and is completely free to use.

By accessing the services available at ADVFN you are agreeing to be bound by ADVFN's Terms & Conditions

P: V: D:20191018 03:58:21